SILO
Silo Pharma, Inc.Company with tickers: SILO
CIK
1514183
CUSIP
82711P201
Shares Outstanding
1,084,440
13F Activity (30d)
12 filings
12 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $18,026 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $20,688 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Gross Profit | $-2,662 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Expenses | $1,591,998 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $1,013,265 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-1,594,660 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-1,647,117 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.12 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |